Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) was founded in 2004 and is headquartered in Cambridge, Massachusetts, USA, with 17 full-time employees. It is a clinical-stage biopharmaceutical company focusing on the development of prostate-specific drugs in the United States. New patented therapies for cancer and other hormone-driven diseases.
On May 10, 2017, Otic Pharma completed its merger with Tokai Pharmaceuticals, and the latter was delisted.
Tokai Pharmaceuticals (TKAI):
The protagonist drug candidate of Tokai Pharmaceuticals is: Galeterone, a highly selective, multi-target, oral small molecule drug, currently in the phase III clinical trial phase of the treatment of anti-castration prostate cancer. Compared with the current therapy, it has a larger Advantage.
Tokai has used Galeterone to treat more than 250 prostate cancer patients and healthy volunteers in the first and second clinical stages. Trials have shown that Galeterone is well tolerated and has shown prostate specific antigen (PSA) in multiple prostate cancer populations. ), marking Galeterone’s role as a star. Currently, Tokai Pharmaceuticals has applied to the FDA to start Phase III clinical trials.
Tokai Pharmaceuticals (TKAI) investment:
The company has been delisted!